Nuclear Fusion Breakthroughs: Billion-Dollar Bet Meets New Science
A fusion firm reportedly raised a billion dollars as quantum computing and materials science advances tackle fusion's toughest hurdles.
Artificial intelligence is reshaping how discovery happens across chemistry, biology, physics, and energy research. Rather than replacing scientists, machine learning models are becoming powerful collaborators—sifting through molecular libraries, predicting protein structures, simulating physical systems, and identifying patterns in datasets too large or complex for traditional analysis. This shift is compressing timelines that once spanned years into months or weeks, particularly in fields like drug discovery, materials science, and clean energy research.
Why now? Three forces are converging: dramatic improvements in generative and predictive AI models, the availability of specialized computing hardware built for scientific workloads, and growing pressure from industry and governments to accelerate breakthroughs in medicine, energy security, and advanced computing. Pharmaceutical companies are racing to embed AI systems directly into drug discovery pipelines, while national labs and tech firms are exploring how quantum computing and machine learning together might unlock advances in areas like fusion energy. At the same time, the computational demands of these AI systems are prompting a closer look at energy consumption—creating both challenges and unexpected opportunities for clean power innovation.
Readers of this hub will find ongoing coverage of how major pharmaceutical and technology companies are deploying AI platforms for drug and materials discovery, how quantum computing is being paired with machine learning to tackle previously intractable scientific problems, and how the energy costs of AI infrastructure are influencing the broader clean energy landscape. Expect reporting on new partnerships, deployed systems, research breakthroughs, and the infrastructure debates shaping the future of scientific discovery—tracking both the promise and the practical trade-offs of AI-accelerated science.
A fusion firm reportedly raised a billion dollars as quantum computing and materials science advances tackle fusion's toughest hurdles.
Accipiter Bio raised $10.5M more from existing investors to speed AI-designed protein drug development and expand its pipeline.
GSK signs a deal worth up to $110M with Relation Therapeutics to build AI models and cellular datasets for new drug discovery.
AI-designed drugs are entering clinical trials as Anthropic, Nvidia, Bristol Myers Squibb, and Generate Biomedicines drive a pharma R&D shift.
Anthropic, Nvidia, Bristol Myers Squibb and Generate Biomedicines fuel a rapid AI-driven transformation of drug discovery and development.
Nuclear fusion funding hit a record $4.5B this year, as materials science and IBM's quantum computing tackle tritium fuel and reaction efficiency.
AI drug discovery gains momentum as MindWalk, Anthropic, Bristol Myers, and Generate Biomedicines pursue faster, tech-driven pharmaceutical R&D.
IBM, Oak Ridge and Cleveland Clinic used quantum computing and AI to model tritium production, tackling a key barrier to nuclear fusion energy.
Bristol Myers Squibb is buying Nvidia's newest AI computing system to accelerate drug discovery, as rivals in the U.S. and China race ahead.
AI is driving surging electricity demand while also speeding up clean energy breakthroughs in batteries, fusion, and materials science.
Bristol Myers Squibb is buying Nvidia's newest AI computing system to speed drug discovery, part of a broader AI research investment wave.